NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL
Pharmaceutical Technology
APRIL 24, 2023
The British institute that oversees a therapy’s cost-effectiveness opted for the recommendation based on clinical data from the Phase II CAPTIVATE and the Phase III GLOW studies. The combination therapy also caused fewer side effects, with heart problems and hypertension as the most common ones, based on the final draft guidance.
52 
Let's personalize your content